Aptose Biosciences (APTO) News Today $2.56 -0.29 (-10.18%) As of 01:32 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Aptose Biosciences Inc. (NASDAQ:APTO) Short Interest UpdateAptose Biosciences Inc. (NASDAQ:APTO - Get Free Report) (TSE:APS) was the recipient of a significant decline in short interest in the month of February. As of February 15th, there was short interest totalling 74,900 shares, a decline of 92.5% from the January 31st total of 993,200 shares. Currently, 3.7% of the shares of the company are sold short. Based on an average trading volume of 397,700 shares, the short-interest ratio is presently 0.2 days.February 28, 2025 | marketbeat.comAptose Biosciences initiated with a Speculative Buy at Alliance Global PartnersFebruary 27, 2025 | markets.businessinsider.comAptose Biosciences trading halted, news pendingFebruary 25, 2025 | markets.businessinsider.comStockNews.com Initiates Coverage on Aptose Biosciences (NASDAQ:APTO)February 25, 2025 | americanbankingnews.comAptose Biosciences approved to escalate dose in Phase 1/2 AML trialFebruary 20, 2025 | markets.businessinsider.comAptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First CohortFebruary 20, 2025 | globenewswire.comAptose Biosciences, Inc.: Aptose Announces Reverse Share SplitFebruary 19, 2025 | finanznachrichten.deAptose Biosciences announces 1-for-30 reverse share splitFebruary 19, 2025 | markets.businessinsider.comAptose Announces Reverse Share SplitFebruary 18, 2025 | globenewswire.comAptose Biosciences files to sell 12.03M shares of common stock for holdersFebruary 13, 2025 | markets.businessinsider.comAptose Biosciences secures $25 million equity facilityFebruary 13, 2025 | msn.comAptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market FacilityFebruary 13, 2025 | globenewswire.comAptose Biosciences' leukemia drug shows early promiseFebruary 12, 2025 | msn.comAptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY TrialFebruary 12, 2025 | finance.yahoo.comAptose's Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY TrialFebruary 12, 2025 | globenewswire.comAptose Biosciences shareholders approve reverse stock splitJanuary 29, 2025 | msn.comAptose Biosciences faces Nasdaq delisting over share priceJanuary 21, 2025 | msn.comAptose Biosciences Inc APSJanuary 16, 2025 | morningstar.comAptose Biosciences: Positive Outlook and Buy Rating Backed by Promising Tuspetinib Developments in AML TreatmentJanuary 11, 2025 | markets.businessinsider.comAptose announces first AML patients dosed in TUSCANY trialJanuary 10, 2025 | markets.businessinsider.comAptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY TrialJanuary 9, 2025 | globenewswire.comWall Street Set to Open Lower Friday; Key Inflation Data Lower Than ExpectedDecember 20, 2024 | msn.comAptose Biosciences, Inc.: Aptose Announces Positive Decision by Nasdaq Hearings PanelDecember 20, 2024 | finanznachrichten.deAptose Biosciences granted extension to regain compliance with NasdaqDecember 19, 2024 | markets.businessinsider.comAptose Announces Positive Decision by Nasdaq Hearings PanelDecember 19, 2024 | globenewswire.comAptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib's Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with VenetoclaxDecember 12, 2024 | globenewswire.comPromising Potential of Aptose Biosciences in AML Treatment Drives Buy RatingDecember 11, 2024 | markets.businessinsider.comAptose Biosciences announces clinical data on tuspetinibDecember 9, 2024 | markets.businessinsider.comAptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AMLDecember 9, 2024 | globenewswire.comStrategic Collaboration and Promising Pipeline Drive Buy Rating for Aptose BiosciencesDecember 6, 2024 | markets.businessinsider.comAptose Biosciences signs CRADA with NCI to develop tuspetinib for AML, MDSDecember 4, 2024 | markets.businessinsider.comAptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine TrialsDecember 3, 2024 | financialpost.comAptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine TrialsDecember 3, 2024 | globenewswire.comWilliam G. Rice Purchases 100,000 Shares of Aptose Biosciences Inc. (NASDAQ:APTO) StockNovember 27, 2024 | insidertrades.comAptose Biosciences Inc. Announces Closing of $8 Million Public OfferingNovember 25, 2024 | financialpost.comAptose Biosciences Inc. Announces Closing of $8 Million Public OfferingNovember 25, 2024 | financialpost.comAptose Biosciences Inc. Announces Closing of $8 Million Public OfferingNovember 25, 2024 | globenewswire.comAptose Biosciences to sell 40M shares at 20c in public offeringNovember 23, 2024 | markets.businessinsider.comAptose Biosciences Inc. Announces Pricing of $8 Million Public OfferingNovember 22, 2024 | globenewswire.comAptose Biosciences, Inc.: Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet TherapyNovember 21, 2024 | finanznachrichten.deAptose Biosciences initiates TUSCANY Phase 1/2 studyNovember 21, 2024 | markets.businessinsider.comAptose Biosciences price target lowered to $2 from $7 at H.C. WainwrightNovember 21, 2024 | markets.businessinsider.comAptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet TherapyNovember 20, 2024 | globenewswire.comAptose Biosciences Reports Q3 2024 Financial HighlightsNovember 9, 2024 | markets.businessinsider.comAptose Biosciences Advances AML Triplet TherapyNovember 9, 2024 | markets.businessinsider.comAptose Reports Results for the Third Quarter 2024November 8, 2024 | globenewswire.comAptose Biosciences Inc (LTI.BE)September 12, 2024 | sg.finance.yahoo.comAptose Announces Results from Special Meeting of ShareholdersSeptember 5, 2024 | globenewswire.comWall Street Set to Open Shortened Week Lower Tuesday as Investors Await Manufacturing DataSeptember 4, 2024 | msn.comAptose Biosciences secures funds for AML treatment developmentSeptember 3, 2024 | finance.yahoo.com Get Aptose Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter. Email Address APTO Media Mentions By Week APTO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APTO News Sentiment▼0.880.70▲Average Medical News Sentiment APTO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APTO Articles This Week▼71▲APTO Articles Average Week Get Aptose Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Finch Therapeutics Group News Today NKGen Biotech News Today Calidi Biotherapeutics News Today IN8bio News Today Cognition Therapeutics News Today BioAtla News Today Athira Pharma News Today SAB Biotherapeutics News Today Senti Biosciences News Today Chromocell Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APTO) was last updated on 3/4/2025 by MarketBeat.com Staff From Our Partners77 Hedge Funds Are Betting On This Off-Radar MineralWith surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fa...The Tomorrow Investor | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptose Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
